Decoy Therapeutics (DCOY) EBITDA Margin (2016 - 2026)
Decoy Therapeutics (DCOY) posted quarterly EBITDA Margin of 545.48% for Q2 2021, down 39259.0% year-over-year from N/an in Q2 2020, and down 283.53% quarter-over-quarter from 142.23% in Q1 2021.
Decoy Therapeutics (DCOY) EBITDA Margin (2016 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported EBITDA Margin for 6 consecutive years, with 545.48% the latest figure, recorded in Q2 2021.
- In Q2 2021, EBITDA Margin fell 39259.0% year-over-year to 545.48%; the TTM figure through Mar 2022 stood at 2997.19% (down 286270.0% YoY), while the FY2021 annual figure was 696.27%, down 54749.0% from the prior year.
- EBITDA Margin slipped to 545.48% in Q2 2021 per DCOY's latest filing, from 142.23% in the prior quarter.
- Across five years, EBITDA Margin topped out at 66.84% in Q3 2018 and bottomed at 4638.1% in Q1 2018.
- Historically, EBITDA Margin has averaged 1285.32% across 5 years, with a median of 331.77% in 2019.
- Annual changes were most pronounced in 2017 — EBITDA Margin surged 753395 bps — and 2018, when it sank 119702 bps.
- Decoy Therapeutics' EBITDA Margin stood at 2861.44% in 2017, then jumped by 57 bps to 1239.45% in 2018, then jumped by 84 bps to 198.33% in 2019, then jumped by 40 bps to 118.82% in 2020, then sank by 359 bps to 545.48% in 2021.
- Business Quant data shows DCOY's EBITDA Margin at 545.48% in Q2 2021, 142.23% in Q1 2021, and 118.82% in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.75% |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - | -1,155.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,155.84% |
| Jun 30, 2021 | -545.48% |
| Mar 31, 2021 | -142.23% |
| Dec 31, 2020 | -118.82% |
| Sep 30, 2020 | -127.59% |
| Jun 30, 2020 | -152.89% |
| Mar 31, 2020 | -209.17% |
| Dec 31, 2019 | -198.33% |
| Sep 30, 2019 | -429.76% |
| Jun 30, 2019 | -101.82% |
| Mar 31, 2019 | -233.79% |
| Dec 31, 2018 | -1,239.45% |
| Sep 30, 2018 | -66.84% |
| Jun 30, 2018 | -3,708.19% |
| Mar 31, 2018 | -4,638.10% |
| Dec 31, 2017 | -2,861.44% |
| Sep 30, 2017 | -2,275.01% |
| Jun 30, 2017 | -2,645.71% |
| Mar 31, 2017 | -3,441.09% |
| Dec 31, 2016 | -2,742.80% |